Cutaneous Leukemia Inhibitory Factor and Its Potential Role in the Development of Skin Tumors

Dermatologic Surgery

Volumn 30, Issue 2 II, 2004, Pages 279-290

  McKenzie, Roddie C ^a   Szepietowski, Jacek ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR;

CYTOKINE PRODUCTION; HUMAN; HYPERPLASIA; INFLAMMATION; KERATINOCYTE; MAST CELL; PLASTIC SURGERY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; TUMOR GROWTH; ULTRAVIOLET RADIATION; WOUND HEALING;

EID: 1542378214     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042728-200402002-00009     Document Type: Review

References (84)

1. Turnley AM, Bartlett PF. Cytokines that signal through the leukemia inhibitory factor receptor-β complex in the nervous system. J Neurochem 2000;74:889-99.
2. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
3. Metcalfe D. The leukemia inhibitory factor: a puzzling polyfunctional regulator. Growth Factors 1992;7:169-73.
4. Gearing DP. The leukemia inhibitory factor and its receptor. Adv Immunol 1993;53:31-58.
5. Gadient RA, Patterson PH. Leukemia inhibitory factor, interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 1999;17:127-37.
6. Alexander HR, Billingsley KG, Block MI, Fraker DL. D-factor/leukaemia inhibitory factor: evidence for its role as a mediator in acute and chronic inflammatory diseases. Cytokine 1994;6:589-96.
7. Knight D. Leukaemia inhibitory factor (LIF): a cytokine of emerging importance in chronic airway inflammation. Pulm Pharmacol Ther 2001;14:169-76.
8. Hilton DJ, Gough NM. Leukemia inhibitory factor: a biological perspective. J Cell Biochem 1991;46:21-6.
9. Auernhammer CJ, Melmed S. Leukemia inhibitory factor: neuroimmune modulator of endocrine function. Endocr Rev 2000;21:313-45.
10. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314.
11. Patterson PH. Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology. Proc Natl Acad Sci USA 1994;91:7833-5.
12. Murphy M, Dutton R, Koblar S, Cheema S, Bartlett P. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog Neurobiol 1997;52:355-78.
13. Paglia D, Kondo S, Ng K-EM, Sauder DN, McKenzie RC. Leukaemia inhibitory factor is expressed by normal human keratinocytes in vivo and in vitro. Br J Dermatol 1996;134:817-23.
14. Thoma B, Bird TA, Friend DJ, Gearing DP, Dower SK. Oncostatin-M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 1994;269:6215-22.
15. Oh H, Fujio Y, Kunisada K, et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70, S6 kinase phosphorylation in cardiac myocytes. J Biol Chem 1998;16:9703-10.
16. Middleton G, Hamanoue M, Enokido Y, et al. Cytokine-induced nuclear factor kappa B activation promotes the survival of developing neurons. J Cell Biol 2000;148:325-32.
17. Blanchard F, Duplomb L, Wang YP, et al. Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase. J Biol Chem 2000;275:28793-801.
18. Michishita M, Satoh M, et al. Phosphorylation of the stress protein hsp27 is an early event in murine myelomonocytic leukemic-cell differentiation induced by leukemia inhibitory factor D-factor. Biochem Biophys Res Commun 1991;176:979-84.
19. Baumann H, Wong G. Hepatocyte-stimulating factor III shares structural and functional identity with leukemia inhibitory factor. J Immunol 1989;143:1163-7.
20. Akiyama M, Smith LT, Shimizu H. Changing patterns of localization of putative stem cells in developing human hair follicles. J Invest Dermatol 2000;114:321-7.
21. Jones PH, Watt FM. Separation of human epidermal stem-cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 1993;73:713-24.
22. Moles JP, Watt FM. The epidermal stem cell compartment: variation in expression levels of E-cadherin and catenins within the basal layer of human epidermis. J Histochem Cytochem 1997;45:867-74.
23. Hu J, Ono S, Katayama H, et al. Leukemia inhibitory factor induces epidermal hyperplasia in patients with amyotrophic lateral sclerosis. J Invest Dermatol 2000;115:486-92.
24. Szepietowski JC, Walker C, McKenna DB, Hunter JAA, McKenzie RC. Leukaemia inhibitory factor (LIF) and interleukin (IL)-8 expression in non-melanoma skin cancers. Clin Exp Dermatol 2001;26:72-8.
25. Bonifati C, Mussi A, D'Auria L, et al. Spontaneous release of leukemia inhibitory factor and oncostatin M is increased in supermatants of short term organ cultures from psoriatic patients. Arch Dermatol Res 1998;290:9-13.
26. Szepietowski JC, Walker C, Hunter JAA, McKenzie RC. Elevated leukaemia inhibitory factor in lesional psoriatic skin: correlation with interleukin-8 expression. J Dermatol 2001;28:115-22.
27. Komine M, Freedgerg IM, Blumenberg M. Regulation of epidermal expression of keratin K17 in inflammatory skin diseases. J Invest Dermatol 1996;107:569-75.
28. Markey AC, Lane EB, Macdonald DM, Leigh IM. Keratin expression in basal-cell carcinomas. Br J Dermatol 1992;126:154-60.
29. Akita S, Ishihara H, Abdur RM, Fujii T. Leukemia inhibitory factor gene improves skin allograft survival in the mouse model. Transplant 2000;70:1026-31.
30. Waring P, Wycherley K, Cary D, Nicola N, Metcalf D. Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids. J Clin Invest 1992;90:2031-7.
31. Villers D, Dao T, Nguyen JM, et al. Increased plasma-levels of human interleukin for DA1A cells leukemia inhibitory factor in sepsis correlate with shock and poor-prognosis. J Infect Dis 1995;171:232-6.
32. Taupin JL, Morel D, Moreau JF, et al. HILDA/LIF urinary excretion during acute kidney rejection. Transplantation 1992;53:655-8.
33. Jansen PM, deJong IW, Hart M, et al. Release of leukemia inhibitory factor in primate sepsis: analysis of the role of TNF-alpha. J Immunol 1996;156:4401-7.
34. Block MI, Berg M, McNamara M, et al. Passive immunization of mice against D-factor blocks lethality and cytokine release during endotoxemia. J Exp Med 1993;173:1085-90.
35. Ikezono T, Wu T, Yao XL, et al. Leukemia inhibitory factor induces the 85-kDa cytosolic phospholipase A (2) gene expression in cultured human bronchial epithelial cells. Biochim Biophys Acta 1997;1355:121-30.
36. McKenzie RC, Paglia D, Kondo S, Sauder DN. Leukemia inhibitory factor: a novel mediator of cutaneous inflammation. Acta Derm Venereol 1996;76:111-4.
37. Thompson SWN, Dray A, Urban L. Leukemia inhibitory factor induces mechanical allodynia but not thermal hyperalgesia in the juvenile rat. Neuroscience 1996;71:1091-4.
38. Carroll GJ, Bell MC, Chapman HM, Mills JN, Robinson WE Leukemia inhibitory factor induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints. J Interferon Cytokine Res 1995;15:567-73.
39. Szepietowski JC, McKenzie RC, Keohane SG, Aldridge RD, Hunter JAA. Leukaemia inhibitory factor: induction in the early phase of allergic contact dermatitis. Contact Dermatitis 1997;36:21-5.
40. Banner LR, Patterson PH, Allchorne A, Poole S, Woolf CJ. Leukemia inhibitory factor is an anti-inflammatory and analgesic cytokine. J Neurosci 1998;18:5456-62.
41. Sugiura S, Lahav R, Han J, et al. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur J Neurosci 2000;12:457-66.
42. Zhu M, Oishi K, Lee SC, Patterson PH. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J Immunol 2001;166:2049-54.
43. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003;24:25-9.
44. Weber S, Kruger-Krasagakes, Grabbe J, Zuberbier T, Czarnetzki BM. Mast cells. Int J Dermatol 1995;34:1-10.
45. Henz BM, Maurer M, Lippert U, Worm M, Babina M. Mast cells as initiators of immunity and host defense. Exp Dermatol 2001;10:1-10.
46. Marshall J, Gauldie J, Nielsen L, Bienenstock J. Leukemia inhibitory factor production by rat mast cells. Eur J Immunol 1993;23:2116-20.
47. Tanaka T, Morita E, Mihara S, Kanno M, Yamamoto S. Identification of leukemia inhibitory factor as a potent mast cell growth-enhancing factor produced by mouse keratinocyte cell line, KCMH-1. Arch Dermatol Res 2001;293:18-25.
48. Nakamura K, Tanaka T, Morita E, Kamayoshi Y, Yamamoto S. Enhancement of fibroblast-dependent mast cell growth in mice by a conditioned medium of keratinocyte-derived squamous carcinoma cells. Arch Dermatol Res 1994;293:18-25.
49. Gyotoku E, Morita E, Kameyoshi Y, et al. The IL-6 family cytokines interleukin-6, interleukin-11, oncostatin M and leukemia inhibitory factor, enhance mast cell growth through fibroblast-dependent pathway in mice. Arch Dermatol Res 2001;293:508-14.
50. Lascano EF. Mast cells in human tumours. Cancer 1958;11:1110.
51. Cawley EP, Hoch-Ligeti C. Association of tissue mast cells and skin tumours. Arch Dermatol 1961;83:146-50.
52. Cohen MS, Rogers GS. The significance of mast cells in basal carcinoma. J Am Acad Dermatol 1994;33:514-7.
53. Grimbaldeston MA, Skov L, Finlay-Jones JJ, Hart PH. Squamous cell carcinoma is not associated with high dermal mast cell prevalence in humans. J Invest Dermatol 2002;119:1204-5.
54. Reed JA, McNutt NS, Bogdany JK, Albino AP. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. J Cutan Pathol 1996;23:495-505.
55. Duncan LM, Richards LA, Mihm MC. Increased mast cell density in invasive melanoma. J Cutan Pathol 1998;25:11-5.
56. Humphreys TR, Monteiro MR, Murphy GF. Mast cells and dendritic cells in basal cell carcinoma stroma. Dermatol Surg 2000;26:200-3.
57. Blair RJ, Meng H, Marchese MJ, et al. Human mast cells stimulate vascular tribe formation: tryptase is a novel, potent angiogenic factor. J Clin Invest 1997;99:2691-700.
58. Cabanillas-Saez A, Schalper JA, Nicovani SM, Rudolph MI. Characterization of mast cells according to their content of tryptase and chymase in normal and neoplastic human uterine cervix. Int J Gynecol Cancer 2002;12:92-8.
59. Deng JS, Brod BA, Saito R, Tharp MD. Immune-associated cells in basal cell carcinomas of skin. J Cutan Pathol 1996;23:140-6.
60. Sagher F, Even-Paz Z. Mastocytosis and the Mast Cell. Basel: S. Karger, 1967:299-301.
61. Ackermann L, Harvima IT, Pelkonen J, et al. Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol 1999;140:624-33.
62. Torunoiwa B, Jablonska S. Mast cells in the initial stages of psoriasis. Arch Dermatol Res 1988;280:189-93.
63. Kondo S, Kooshesh F, Sauder DN. Penetration of keratinocyte-derived cytokines into basement membrane. J Cell Physiol 1997;171:190-5.
64. Paglia D, Oran A, Lu C, et al. Expression of leukemia inhibitory factor and interleukin-11 in human melanoma lines: LIF, IL-6 and IL-11 are not co-regulated. J Interferon Cytokine Res 1995;14:455-60.
65. Heymann D, Harb J, Ringeard S, et al. Upmodulation of alpha-v-beta-1 integrin expression on human tumor-cells by human interleukin for DA-cells leukemia inhibitory factor and oncostatin-M: correlation with increased cell-adhesion on fibronectin. J Cell Biochem 1995;58:305-14.
66. Heymann D, Godard A, Raher S, et al. Human interleukin for DA cells leukemia inhibitory factor and oncostatin-M enhance membrane expression of intercellular-adhesion molecule-1 on melanoma-cells but not the shedding of its soluble form. Cytokine 1995;7:111-7.
67. Mori M, Yamaguchi K, Honda S, et al. Cancer cachexia syndrome developed in nude-mice bearing melanoma-cells producing leukemia-inhibitory factor. Cancer Res 1991;51:6656-9.
68. Burg C, Patry Y, Lependu J, et al. Leukemia inhibitory factor derived from rat colon carcinoma cells increases host susceptibility to tumour growth. Cytokine 1995;7:784-92.
69. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 1998;48:165-74.
70. Miettinen M, Nobel MP, Tuma BT, Kovatich AJ. Keratin 17: immunohistochemical mapping of its distribution in human epithelial tumours and its potential applications. Appl Immunochem 1997;5:152-9.
71. Yoshikawa K, Katagata Y, Kondo S. Biochemical and immunohistochemical analyses of keratin expression in basal cell carcinoma. J Dermatol Sci 1998;17:15-23.
72. Schiemann WP, Bartoe JL, Nathanson NM. Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase: evidence for participation of multiple signaling pathways which converge at Ras. J Biol Chem 1997;272:16631-6.
73. Dajee M, Lazarov M, Zhang JY, et al. NF-kappa B blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421:639-43.
74. Sato M, Sawamura D, Ina S, et al. In vivo introduction of the interleukin 6 gene into human keratinocytes: induction of epidermal proliferation by the fully spliced form of interleukin 6, but not by the alternatively spliced form. Arch Dermatol Res 1999;291:400-4.
75. Elder JT, Sartor CI, Boman DK, et al. Interleukin-6 in psoriasis: expression and mitogenicity studies. Arch Dermatol Res 1992;284:324-32.
76. Gallucci RM, Simeonova PP, Matheson JM, et al. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J 2000;14:2525-31.
77. Nishimura N, Tohyama C, Satoh M, Nishimura H, Reeve VE. Defective immune response and severe skin damage following UVB irradiation in interleukin-6-deficient mice. Immunology 1999;97:77-83.
78. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104:1527-37.
79. Toyoda M, Nakamura M, Makino T, Hino T, Morohashi M. Physiological activities of keratinocyte-derived ciliary neurotrophic factor in human skin and its pathogenic involvement in cutaneous inflammatory diseases. J Invest Dermatol 2001;117:214.
80. Ono S, Imai T, Shimizu N, Nakagawa H, Hu J. Ciliary neurotropic factor in skin biopsies of patients with amyotrophic lateral sclerosis. Lancet 1998;352:958-9.
81. Scordi IA, Vincek V. Time course study of UVB-induced cytokine induction in whole mouse skin. Photodermatol Photoimmunol Photomed 2000;16:67-73.
82. McKenzie RC. Ultraviolet radiation B (UVB): induction of leukaemia inhibitory factor (LIF) in human keratinocytes. Photodermatol Photoimmunol Photomed 2001;17:284-5.
83. Duthie MS, Kimber I, Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol 1999;140:995-1009.
84. Hirobe T. Role of leukemia inhibitory factor in the regulation of the proliferation and differentiation of neonatal mouse epidermal melanocytes in culture. J Cell Physiol 2002;192:315-26.